HELIX BIOPHARMA CORP. INITIATES ENROLLMENT FOR THIRD COHORT AND EXPANSION OF CENTRES

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the third dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion of the first treatment cycle …

Helix BioPharma Corp. announces L-DOS47 scientific presentation to be made at BIT LifeScience’s 5th International Congress of Antibodies

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that Helix’s Chief Science Officer, Dr. Heman Chao, will be making a presentation relating to Helix’s L-DOS47 platform at BIT LifeScience’s 5th International Congress of Antibodies in Hangzhou, China on March 19, 2013. Dr. Chao’s presentation, …

HELIX BIOPHARMA CORP. ANNOUNCES Q2 FISCAL 2013 RESULTS

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced its financial results and research and development update for the three and six month periods ended January 31, 2013 and 2012. HIGHLIGHTS DURING THE FISCAL QUARTER ENDED JANUARY 31, 2013 On December 14, 2012 the Company …

HELIX BIOPHARMA ANNOUNCES DIRECTOR RESIGNATION

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that William B. White voluntarily resigned from Helix’s board of directors with effect from February 22, 2013. Commenting on the resignation, Mario Gobbo, Chairman of the Board of Helix said, “Over the past eleven months, Bill …

HELIX BIOPHARMA CORP. ANNOUNCES EXTENSION OF 2009 WARRANT EXPIRY DATE

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that it has applied to the Toronto Stock Exchange to extend the expiry date of the 2009 Warrants (as defined below) by six months, from March 7, 2013 at 5:00 p.m. (Toronto time) (the “Current Expiry …

HELIX BIOPHARMA ANNOUNCES APPOINTMENT OF DIRECTOR

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of Andrew J. MacDougall to the board of directors, effective immediately, in order to satisfy the statutory requirement for resident Canadians to comprise at least 25% of the board of directors pending completion of …

HELIX BIOPHARMA ANNOUNCES DIRECTOR RESIGNATION

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announced that on Friday, February 8, 2013 John A. Rogers has voluntarily resigned from Helix’s board of directors. About Helix BioPharma Corp. Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company …

HELIX ANNOUNCES COMPLETION OF THE SALE OF ITS RIVEX PHARMA DIVISION TO PHARMASCIENCE

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announced today the completion of the previously announced sale of its Rivex Pharma division to Pharmascience Inc. (“Pharmascience”) for gross cash proceeds of $8.5 million, subject to adjustment (the “Rivex Transaction”). The Rivex Transaction was approved by …

HELIX ANNOUNCES SHAREHOLDER APPROVAL FOR THE SALE OF ITS RIVEX PHARMA DIVISION TO PHARMASCIENCE AND OTHER RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announces that its Annual General and Special Meeting (the “Shareholder Meeting”) was held today as scheduled. At the Shareholder Meeting, Helix received approval of 100% of the votes cast by shareholders present, in person or by proxy, …